Myriad Genetics, Inc [MYGN] stock prices are down -0.15% to $6.57 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MYGN shares have gain 7.00% over the last week, with a monthly amount drifted -9.13%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Myriad Genetics, Inc [NASDAQ: MYGN] stock has seen the most recent analyst activity on May 21, 2025, when Scotiabank downgraded its rating to a Sector Perform but kept the price target unchanged to $6 for it. Previously, Wolfe Research downgraded its rating to Peer Perform on May 08, 2025. On May 07, 2025, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $6 on the stock. Guggenheim downgraded its rating to a Neutral. Piper Sandler upgraded its rating to an Overweight and raised its price target to $12.50 on March 12, 2025. Craig Hallum started tracking with a Buy rating for this stock on February 12, 2025, and assigned it a price target of $29. In a note dated December 10, 2024, UBS initiated a Neutral rating and provided a target price of $18 on this stock.
The stock price of Myriad Genetics, Inc [MYGN] has been fluctuating between $3.76 and $15.47 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Myriad Genetics, Inc [NASDAQ: MYGN] shares were valued at $6.57 at the most recent close of the market. An investor can expect a potential return of 21.77% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
The Myriad Genetics, Inc [NASDAQ:MYGN] reported sales of 825.30M for trailing twelve months, representing a drop of -3.56%. Gross Profit Margin for this corporation currently stands at 0.7% with Operating Profit Margin at -0.51%, Pretax Profit Margin comes in at -0.52%, and Net Profit Margin reading is -0.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.74 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Myriad Genetics, Inc [NASDAQ:MYGN]’s Current Ratio is 2.33. Further, the Quick Ratio stands at 2.12, while the Cash Ratio is 0.98. Considering the valuation of this stock, the price to sales ratio is 0.74, the price to book ratio is 1.64.
